Physician profile
Zeeshan K Tayeb
NPI 1659537785
$16,884.37
in general payments reported to CMS, 2019-2025
28 companies · $9,526 in 2025
The $9,526 reported for 2025 was more than what 97% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $125 · 2021: $3,186 · 2022: $226 · 2023: $558 · 2024: $2,740 · 2025: $9,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,725 · Travel and Lodging: $4,636 · Food and Beverage: $3,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,725.00 |
| Travel and Lodging | $4,636.23 |
| Food and Beverage | $3,462.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,684.27 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $1,393.84 | 2019-2025 | G4 Rf Generator, General - Pain Management |
| Collegium Pharmaceutical, INC. | $275.61 | 2019-2024 | Xtampza |
| Curonix LLC | $265.32 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.37 | 2021-2024 | Relistor |
| Vertex Pharmaceuticals Incorporated | $142.54 | 2025 | |
| Si-Bone, INC. | $114.69 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $107.37 | 2021 | |
| Abbvie INC. | $97.33 | 2021-2025 | |
| Vertos Medical, INC. | $89.19 | 2021 | |
| Heron Therapeutics, INC. | $82.95 | 2019 | |
| Zyla Life Sciences, INC. | $66.87 | 2019-2020 | |
| Saluda Medical Americas, INC. | $56.10 | 2024 | Evoke |
| Stimwave Technologies Incorporated | $51.00 | 2021 | |
| Redhill Biopharma INC. | $30.36 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $29.75 | 2024 | Prolate, Nalocet |
| Amgen INC. | $29.58 | 2020-2021 | |
| Painteq LLC | $25.90 | 2024 | Painteq |
| Bioventus LLC | $22.60 | 2022 | |
| Medtronic USA, INC. | $18.24 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $16.50 | 2021 | |
| Valinor Pharma, LLC | $16.31 | 2025 | Movantik |
| Novartis Pharmaceuticals Corporation | $16.16 | 2019 | |
| Indivior INC. | $15.85 | 2024 | Sublocade |
| Scilex Pharmaceuticals INC. | $14.16 | 2025 | |
| Grt US Holding, INC. | $11.98 | 2021 | |
| Kaleo, INC. | $11.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeeshan Tayeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.